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Background: Liposarcoma (LS) is the second-most common type of soft-tissue sarcoma. Despite advances in
knowledge and treatment of this disease, there remains a need for more effective LS therapy. Steroid hormone
receptors regulate metabolism in adipocytes. Estrogen receptor alpha (ER), progesterone receptor (PR), and androgen
receptor (AR) have been implicated in the pathophysiology of other cancer types. We sought to comprehensively
determine temporal expression patterns of these receptors in LS.
Methods: We analyzed 561 histologically subtyped LS specimens from 354 patients for expression of ER, PR, and
AR by immunohistochemistry (IHC) using diagnostic-grade reagents and protocols. The fractions of positively stained
tumor cells were scored within each specimen. IHC scores were compared across LS subtypes using the Kruskal-Wallis
test, and subtypes were compared using Dunn’s post-hoc test. Ages of patients with receptor-positive vs. -negative LS
were compared by t-test. Genders and races were compared for hormone receptor positivity using Fisher’s exact test
and Chi-square analysis, respectively. Recurrence-free survival was compared between receptor-positive and negative
patients by log-rank test. p< 0.05 was considered significant.
Results: ER and AR were frequently expressed in LS, while few tumors expressed PR. Most of the ER + and AR +
samples were of the well-differentiated LS subtype. A smaller fraction of de-differentiated LS expressed ER or AR, but
expression was common within well-differentiated regions of tumors histologically classified as de-differentiated LS. In
LS specimens from patients who underwent multiple surgeries over time, receptor expression frequently changed over
time, which may be attributable in part to intratumor heterogeneity, varying degrees of de-differentiation, and biopsy
bias. ER and AR were frequently co-expressed. Receptor status was not significantly associated with gender or race, but
AR and PR expression were associated with earlier age at diagnosis. Receptor expression was not associated with
altered recurrence-free survival.
Conclusions: ER and AR are commonly expressed in LS, particularly in well-differentiated tumors. These data warrant
further functional study to determine receptor function in LS, and the potential efficacy of anti-hormone therapies for
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Approximately 11,280 patients are diagnosed with one of
many types of soft tissue sarcoma each year in the U.S.
[1]. Liposarcomas (LS) constitute approximately 24% of
extremity and 45% of retroperitoneal soft tissue sarco-
mas [2], ranking as the second-most common type of
soft-tissue sarcoma. LS occurs in three major biologic
subgroups: 1) well- or de-differentiated LS (WDLS, DDLS,
most common subgroup), 2) myxoid LS (MLS), and 3)
pleomorphic LS (PLS). WDLS and MLS are typically low-
grade tumors, DDLS are often intermediate grade with
intermediate risk for metastasis, and PLS are high-grade
and clinically aggressive. It is thought that DDLS starts as
WDLS, and tumor cells progressively accumulate genetic
lesions as they transition to a less differentiated, non-
lipogenic state. Progression to DDLS is associated with
more aggressive local disease, increased metastatic poten-
tial (10-20%), and increased mortality (50-75%) [3-6]. LS
is typically treated by surgical resection, and high-grade
lesions are sometimes treated with adjuvant radiation
therapy. DNA-damaging chemotherapy is usually not
effective against LS. In addition, tumor recurrence is
common, particularly with retroperitoneal LS. There-
fore, there exists a need for improved LS therapy.
LS likely originates from a lipogenic precursor cell(s).
Since lipogenic metabolism is heavily influenced by steroid
hormones [7], and adipocytes express nuclear hormone
receptors and steroidogenic enzymes such as aromatase
[8,9], we postulated that LS cells may similarly express
such receptors. Prior studies in limited numbers of pa-
tients reported expression of steroid hormone receptors in
a fraction of LS cases [10-17]. To expand upon and clarify
these findings, we analyzed 561 LS specimens acquired
from 353 patients in the largest LS cohort reported to-
date to determine the frequencies of expression of estro-
gen receptor alpha (ER), progesterone receptor (PR), and
androgen receptor (AR). Frequent expression of these
hormone receptors may prompt clinical testing of anti-
hormone strategies, such as those used to treat patients
with cancers of the breast (anti-estrogens) or prostate
(anti-androgens), or to control pregnancy (anti-proges-
tins), in order to assess the contribution of these receptors
to LS growth. These drugs may ultimately prove useful for
the treatment of patients with LS.
Methods
Patients and tissues
LS specimens were obtained at Dartmouth-Hitchcock
Medical Center and M.D. Anderson Cancer Center be-
tween 1986 and 2012 under protocols approved by the
Institutional Review Boards of Dartmouth-Hitchcock
Medical Center and M.D. Anderson Cancer Center, re-
spectively. Patients provided written informed consent.
Tissues were formalin-fixed and paraffin-embedded.Core samples were used to construct tissue microarrays
(TMAs). Clinical records indicated that these TMAs
included 379 tumors from 353 patients, where tumors
were classified as DDLS (n= 122), WDLS (n= 146), MLS
(n= 79), or PLS (n= 32). WDLS and DDLS are thought
to represent different stages of disease progression that
can co-exist in the same tumor. Hence, some cores
taken from DDLS cases were histologically classified as
“WDLS.” In total, we analyzed 561 core samples, which
were classified as 294 WDLS, 123 DDLS, 112 MLS, and
32 PLS based on histological criteria.
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Commercially available antibodies against ER alpha
(6 F11 monoclonal, dil. 1:35; Leica Biosystems), PR
(PgR 1294 monoclonal, dil. 1:200; Dako; recognizes
both A and B isoforms), and AR (AR441 monoclonal,
dil. 1:30; Dako; recognizes both A and B isoforms) were
used for immunohistochemistry (IHC). These anti-
bodies are routinely used for in vitro diagnostics in
clinical laboratories. A Leica BOND-MAX automated
stainer was used with a polymer/HRP detection sys-
tem. After deparaffinization, 5-μm TMA sections were
treated with citrate buffer at 100°C for 25–30 minutes.
Slides were probed with primary antibody for 15 minutes,
washed, and probed with HRP-polymer anti-mouse IgG for
8 minutes. Signal was detected using 3,3-diaminobenzidine,
followed by hematoxylin counterstaining. ER+/PR + breast
tumor tissue was used as a positive control for ER and PR
IHC. AR + prostate cancer tissue was used as a positive
control for AR IHC. Spleen biopsies were included in the
TMAs and used as negative control tissues. Tissues were
scored based on the estimated percent of positively stained
cancer cell nuclei.Statistics
IHC scores were compared across LS subtypes using the
Kruskal-Wallis non-parametric test, and subtypes were
compared in a one-by-one fashion using Dunn’s post-hoc
test. Ages of patients with hormone receptor-positive
vs. -negative WDLS/DDLS were compared by t-test.
Genders and races were compared for hormone receptorFigure 1 Steroid hormone receptor expression in LS. Sections of LS we
two representative microscopic fields that were scored as receptor-positivepositivity using Fisher’s exact test and Chi-square analysis,
respectively. p ≤ 0.05 was considered significant.Results
Frequent expression of ER and AR in WDLS and DDLS
IHC staining of 561 specimens obtained from 379 LS
tumors from 353 patients (characteristics listed in Table 1)
revealed nuclear ER and AR expression in a significant
number of cases (Figure 1). PR staining was less frequently
observed. Using the stringent threshold of 10% positively-
stained nuclei, we observed the following: 43.1% of
WDLS, 17.5% of DDLS, 0% of PLS, and 5.2% of MLS
were scored as ER+; 9.8% of WDLS, 7.6% of DDLS, 0%
of PLS, and 5% of MLS were scored as PR+; 58.1% of
WDLS, 24.1% of DDLS, 6.2% of PLS, and 9.1% of MLS
were scored as AR + (Figure 2A). Using the threshold
of 1% positively-stained nuclei used in the histological
classification of breast cancer, we observed the follow-
ing: 52.8% of WDLS, 22.5% of DDLS, 3.3% of PLS, and
10.4% of MLS were scored as ER+; 16.5% of WDLS,
10.2% of DDLS, 0% of PLS, and 9% of MLS were scored
as PR+; 70% of WDLS, 36.2% of DDLS, 15.6% of PLS,
and 19.2% of MLS were scored as AR + .
Since a significant number of specimens expressed ER
or AR, we compared IHC scores between histologic sub-
types. We detected a statistically significantly higher fre-
quency of ER and AR expression in WDLS compared to
each other subtype (Figure 2B, all p< 0.001). While some
DDLS specimens expressed ER and AR, this subtype
was not significantly different from PLS or MLS. PR wasre stained using antibodies against A) ER, B) AR, or C) PR. Shown are
or -negative. Scale bar in (A) is 50 μm.
Figure 2 Steroid hormone receptor expression is most common in WDLS. A) LS specimens were scored for% positively-stained nuclei for
ER, PR, and AR, then classified by histological subtype and binned according to score as indicated. B) ER and AR scores were compared between
specimen subtypes. Colored bars indicate mean + SD. *p< 0.0001 by Dunn’s post-hoc test. C) Venn diagrams illustrating the number of WDLS and
DDLS specimens with co-expression of hormone receptors using a threshold of 1% or 10% positively-stained nuclei.
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subtypes.
We then used Venn diagrams to determine the frequency
of receptor co-expression within the combined WDLS
and DDLS subtypes. Among 347 WDLS/DDLS specimens
for which ER and AR IHC were evaluable, ER and AR
were co-expressed in 28% and 22.8% of specimens at the
10% and 1% thresholds, respectively (Figure 2C).Intratumor heterogeneity in ER and AR expression
We observed that hormone receptor expression some-
times differed between tumors acquired from the same
patient who underwent multiple surgeries over time. We
therefore systematically evaluated hormone receptor ex-
pression levels over time in 53 patients who underwent ≥2
surgeries to remove WDLS and/or DDLS (Figure 3). This
analysis revealed that many tumors show changes in
Figure 3 Changes in tumor hormone receptor status over time. Fifty-three patients with WDLS and/or DDLS for whom specimens were
obtained from ≥2 surgeries ≥6 months apart were evaluated. In cases where multiple specimens were obtained from the same tumor at the
same time point, the% positively-stained nuclei were averaged across specimens. The% positively-stained nuclei and histological classification of each
tumor are noted by color intensity and hash marks as indicated in legend.
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Figure 4 Intratumor heterogeneity in degree of differentiation contributes to heterogeneity in hormone receptor expression.
A) Frequencies of hormone receptor expression among WDLS specimens obtained from tumors classified as DDLS. B) Tumors for which
2 specimens were obtained from different regions at the same time point were evaluated for concordance in hormone receptor expression using a
threshold of 10% for positivity. Scatterplots show% positive nuclei for ER and AR in tumors for which one DDLS specimen and one WDLS specimen
were available. C) Representative liposarcoma specimens showing regions of receptor-positivity and -negativity. D) Hormone receptor status for
patients with WDLS/DDLS as determined using any LS specimen obtained from any surgery.
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attributable in part to intratumor heterogeneity, varying
degrees of de-differentiation, and biopsy bias.
DDLS represents a form of tumor progression in WDLS,
and both histologies may co-exist within the same tumor.
We evaluated DDLS tumors with synchronous foci of
WDLS and DDLS histologies for hormone receptor ex-
pression. At a threshold of 10% positively-stained nuclei,
40.8%, 10.3%, and 48.5% of WDLS foci were ER+, PR+,
and AR+, respectively. At a 1% threshold, 54.1%, 15.5%,
and 65.3% of WDLS foci were ER+, PR+, and AR+, respect-
ively (Figure 4A). Therefore, ER and AR expression are
common in WDLS foci within otherwise DDLS tumors.
We then determined the rate of concordance for hor-
mone receptor expression between 2 specimens obtained
from different regions of the same WDLS/DDLS tumor;
75 tumors were available for this analysis. Using a thresh-
old of 10% positively-stained nuclei, this analysis revealed
rates of 58% and 53% concordance for ER and AR, re-
spectively (Figure 4B). Ninety-two percent (69/75) of these
tumors had specimens histologically classified as WDLS
and DDLS (one of each). Among the ER-discordant tu-
mors, 82.8% (24/29) showed an ER +WDLS specimen
and an ER- DDLS specimen (Figure 4B). Among the AR-
discordant tumors, 73.7% (28/38) showed an AR +WDLS
specimen and an AR- DDLS specimen. These data suggestTable 2 Receptor positivity at any time point
n Age (years)
ER Negative 117 60.6 ± 11.8
Positive 102 59.6 ± 11.1
Undetermined 24
Total 243
PR Negative 203 60.4 ± 11.3
Positive 28 56.4 ± 13.2
Undetermined 12
Total 243
AR Negative 90 61.3 ± 11.8
Positive 134 58.6 ± 11.4
Undetermined 19
Total 243that the high degree of intratumor discordance in ER and
AR expression (demonstrated with representative speci-
mens in Figure 4C) is partially attributable to the degree
of de-differentiation.
Given that tumor hormone receptor status changed
over time (Figure 3), we evaluated associations between
patient characteristics and hormone receptor expression
using hormone receptor status (threshold of 10% positively-
stained nuclei) determined from A) a specimen obtained
from the first surgery performed at M.D. Anderson
Cancer Center, or B) hormone receptor positivity from a
specimen obtained from any WDLS/DDLS surgical spe-
cimen (i.e., patient had a receptor-positive specimen
at any time point; frequencies shown in Figure 4D). The
latter criterion indicated that 48.9% and 60.3% of patients
had ER + or AR +WDLS/DDLS at some point during the
course of their disease. Hormone receptor status was not
significantly associated with gender, race, or tumor size.
There was a significant association linking AR expression
with earlier age at WDLS/DDLS diagnosis, and a trend
linking PR expression with earlier age at diagnosis
(Tables 2 and 3). However, the mean ages of onset
were similar between receptor-positive and -negative
groups. ER and AR expression were not associated with
recurrence-free survival in patients with WDLS and/or
DDLS using either criterion.Gender
t-test p Male Female Fisher's p
74 43








0.09 83 51 NS
9 10
144 99
Table 3 Receptor positivity at time of first surgery
Gender
n Age (years) t-test p Male Female Fisher's p
ER Negative 124 60.9 ± 11.3 80 44
Positive 90 59.1 ± 11.6 NS 50 40 NS
Undetermined 29 14 15
Total 243 144 99
PR Negative 202 60.4 ± 11.3 122 80
Positive 23 55.5 ± 13.7 0.06 11 12 NS
Undetermined 18 11 7
Total 243 144 99
AR Negative 100 61.6 ± 11.6 58 42
Positive 122 58.0 ± 11.5 0.02 76 46 NS
Undetermined 21 10 11
Total 243 144 99
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Given that WDLS have a significantly higher frequency
of ER-positivity and AR-positivity than DDLS, and that
WDLS foci within DDLS tumors are often ER + and/or
AR+, hormone receptor expression is likely associated
with a more differentiated LS phenotype. WDLS is often
locally aggressive and non-metastasizing, is treated with
surgical resection, and occurs repeatedly particularly in
the retroperitoneum or mediastinum. WDLS causes mor-
bidity through uncontrolled local effects on vital organs,
or through de-differentiation and metastasis. Therefore,
therapeutics to control WDLS and prevent de-differentiation
may be clinically valuable.
If ER and AR are functionally important for WDLS/
DDLS cell proliferation or viability, as is observed in other
cancer types such as breast and prostate, anti-hormone
therapies may prevent LS progression. However, we cau-
tion that hormone receptor expression does not necessar-
ily indicate receptor dependence. AR is expressed in
70-90% of breast cancers [18], but clinical testing of anti-
androgen therapy in unselected patients with breast can-
cer met with little success [19]. AR may be functionally
important in certain breast cancer subtypes [20,21], and
clinical testing of anti-androgen therapy in patients with
such subtypes is ongoing. Furthermore, ER + breast tu-
mors frequently co-express PR. Since PR is encoded by an
ER-regulated gene, PR co-expression is typically indicative
of ER function. Surprisingly, most ER + LS specimens are
PR-, raising the possibility that ER is non-functional.
Alternatively, ER may regulate a different set of genes
in LS cells, and/or PR levels may be modulated by
another mechanism (such as phosphorylation by mitogen-
activated protein kinase (MAPK), which promotes degrad-
ation [22]).In vitro evidence to support hormone receptor de-
pendence in LS models would help elucidate receptor
function, but few WDLS cell lines exist, and it is argu-
able whether such cell lines accurately model the disease
(s). Transgenic mice that overexpress IL22 in adipocytes
develop WDLS when fed a high-fat diet [23]. If such
murine LS tumors are hormone receptor-positive, this
may present a useful model to elucidate receptor func-
tionality in LS. There have been no proof-of-principle
clinical trials to evaluate the effects of anti-hormone
therapies in LS based on pre-treatment tumor hormone
receptor status. Another option to explore the role(s) of
hormone receptors in LS would be a pilot presurgical
clinical study, where patients who have undergone a
diagnostic tumor biopsy would be treated with anti-
hormone therapy for 2–3 weeks prior to surgical tumor
resection. The diagnostic (pre-treatment) biopsy tissue is
then compared to the surgical (post-treatment) speci-
men to determine whether levels of hormone receptor-
driven or cell cycle-related genes and proteins have
changed. This strategy may be useful to identify LS pa-
tients who will (or will not) benefit from adjuvant endo-
crine therapy [24].
Conclusions
In summary, we demonstrate that a significant fraction
of WDLS and DDLS express ER and/or AR. The hor-
mone receptor scoring method used herein is not finely
calibrated, which may affect assay sensitivity; however, a
less sensitive scoring method may be more likely to detect
only cases with more robust (and, likely, more biological
important) expression of these receptors. While there ap-
pears to be intratumor heterogeneity in hormone receptor
expression, both between well- and de-differentiated areas
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(which may be partially attributable to biopsy bias), endo-
crine therapeutics may be useful to control hormone
receptor-driven LS cells and mitigate disease progression.
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